Abstract 959O
Background
The safety and activity of gavo-cel is being evaluated in a dose-escalation study in patients (pts) with refractory ovarian cancer, malignant mesothelioma (MPM), cholangiocarcinoma (ChoCa), or non-small cell lung cancer.
Methods
Dose escalation follows a 3+3 design. Autologous T-cells were transduced with a T-cell receptor fusion construct (TRuC™) encoding an anti-MSLN single domain antibody fused to the CD3ε subunit. The TRuC then integrates into native TCRs, allowing HLA-independent T-cell engagement to MSLN on cancer cells. Eligibility required central confirmation of 2+ or 3+ MSLN expression by IHC in ≥50% of tumor cells.
Results
As of April 28th, 2021, 17 pts (12 MPM, 4 ovarian, 1 ChoCa) had received a single IV dose of gavo-cel at 5x107/m2 either alone (dose level [DL] 0, n=1) or after lymphodepletion (LD) (DL1, n=6), at 1x108/m2 either alone (DL2, n=1) or after LD (DL3, n=5), or at 5x108/m2 either alone (DL4, n=1) or after LD (DL5, n=3). Median number of prior therapies was 5 (range, 2-9, immune checkpoint inhibitors 65%, anti-MSLN agents 33%). Bridging therapy was required by 53% of pts. Twelve pts were evaluable for safety and efficacy. One DLT (gr3 pneumonitis at DL1) and 2 gr3 CRS events were reported, both resolving with tocilizumab/corticosteroids. Median target lesion regression was 24% (range 5-75%). DCR was 92%. Two pts with ICI-refractory MPM and 1 with TP53-mutated platinum-resistant ovarian cancer had a PR (ORR 25%), including 1 MPM with a complete metabolic response by PET. After a median follow-up of 7 months, the median PFS was 6 months and the median OS was 13 months. Gavo-cel contained a median of 30.45% naïve transduced T-cells (range, 14.1-56.2). Peak expansion occurred on day 15 (median, 854 copies/μg DNA) at DL1 and on day 7 (median, 10,824 copies/μg DNA) at DL3. No differences in cytokine levels were seen between pts treated at DL1 and DL3. A decrease in soluble MSLN related peptides (median -42.56%) and serum megakaryocyte potentiating factor levels (median -38.57%) was observed post infusion among pts with detectable baseline levels.
Conclusions
The toxicity profile of gavo-cel was manageable. Activity was observed among pts with refractory MSLN-expressing solid tumors. Dose escalation is ongoing to determine the RP2D.
Clinical trial identification
NCT03907852.
Editorial acknowledgement
Legal entity responsible for the study
TCR2 Therapeutics.
Funding
TCR2 Therapeutics.
Disclosure
D.S. Hong: Financial Interests, Institutional, Principal Investigator: TCR2 Therapeutics. S.L. SciMentum: Financial Interests, Institutional, Principal Investigator: TCR2 Therapeutics. J. Tanyi: Financial Interests, Institutional, Principal Investigator: TCR2 Therapeutics. L. MacMullen: Financial Interests, Personal, Full or part-time Employment: TCR2 Therapeutics. L. Jalbert: Financial Interests, Personal, Full or part-time Employment: TCR2 Therapeutics. V.P. Muzithras: Financial Interests, Personal, Full or part-time Employment: TCR2 Therapeutics. K. Zikaras: Financial Interests, Personal, Full or part-time Employment: TCR2 Therapeutics. R.E. O’Cearbhaill: Financial Interests, Institutional, Principal Investigator: TCR2 Therapeutics. A. Quintás-Cardama: Financial Interests, Personal, Full or part-time Employment: TCR2 Therapeutics. R. Hassan: Financial Interests, Institutional, Principal Investigator: TCR2 Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
LBA38 - Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types
Presenter: Petri Bono
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
957O - Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
Presenter: James Gulley
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
958O - Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial
Presenter: Aurélien Marabelle
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA38, 957O and 958O
Presenter: Sebastian Kobold
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Aurélien Marabelle
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Slides
Webcast
Invited Discussant 959O
Presenter: Alessandra Curioni
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Alessandra Curioni
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Slides
Webcast